Phase 2B/3 Double-blinded Placebo-controlled

Phase 2

Completed

• Conditions: Chlamydia Trachomatis Infection
• Interventions: Drug: Placebo; Drug: EVO100

• Registration Number: NCT03107377
• Lead Sponsor: Evofem Inc.

Brief Summary

Phase 2B double-blind placebo-controlled efficacy trial of EVO100 (previously known as Amphora ® Gel) for the prevention of acquisition of urogenital Chlamydia trachomatis infection

Detailed Description

Primary: To determine if intravaginal EVO100 reduces the risk of urogenital Chlamydia trachomatis (CT) infection.

Secondary: To determine if intravaginal EVO100 reduces the risk of urogenital Neisseria gonorrhoeae (GC) infection.

Exploratory:To determine if EVO100 use rate (subject adherence to instructed use) has an effect on proportion of subjects who experience CT or GC infection during the study intervention period.

Primary Outcome Measures: Proportion of subjects who experience urogenital CT infection during the study intervention period (incident infection of CT).

Secondary Outcome Measures: Proportion of subjects who experience urogenital GC infection during the study intervention period (incident infection of GC).

Exploratory Outcome Measures:

* Compliance with EVO100 usage during study (rate of product use adherence).

* Sensitivity analyses of the primary parameter (proportion of subjects who experience at least one CT or GC infection during the study intervention period) will be performed for the following:

* Subjects with ≥20%, ≥40%, ≥60% and ≥80% product use adherence

* Subject Satisfaction

* Sexual satisfaction

Study Timeline

• Study First Submitted: 2017-03-29
• Study First Submitted QC: 2017-04-04
• Study First Posted: 2017-04-11
• Study Start: 2017-11-03
• Primary Completion: 2019-08-22
• Study Completion: 2019-08-22
• Results First Submitted: 2020-06-09
• Status Verified: 2020-07
• Results First Submitted QC: 2020-07-27
• Last Update Submitted: 2020-07-27
• Results First Posted: 2020-08-12
• Last Update Posted: 2020-08-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 860

Inclusion Criteria

1. Healthy female subjects between 18 and 45 years, inclusive

2. Ability to understand the consent process and procedures

3. Subjects agree to be available for all study visits

4. Written informed consent in accordance with institutional guidelines

5. Negative pregnancy test

6. Negative CT and GC NAAT tests OR positive CT or GC NAAT and receives standard of care (SOC) treatment

7. Agree to use a woman-controlled method of contraception, such as oral contraceptives, vaginal ring, birth control implants, IUDs, or tubal ligation (with the exception of spermicides, diaphragms, or any vaginally applied or inserted products containing nonoxynol-9). Condom use only is not an acceptable form of contraception for this study.

8. Able and willing to comply with all study procedures

9. Documented (as part of a retrievable medical record) CT or GC infection within 16 weeks prior to enrollment

10. Reports vaginal sexual intercourse with a male partner at least 3 times per month in the previous month and anticipates vaginal sexual intercourse regularly for the duration of the study

11. Agree to abstain from douching or any form of vaginal suppository use (other than study product) during course of study

Exclusion Criteria

1. Participation in any study with an investigational compound or device within 30 days prior to signing informed consent

2. In the opinion of the Investigator, have a history of substance abuse in the last 12 months

3. In the opinion of the Investigator, have issues, conditions, or concerns that may compromise the safety of the subject, impact the subject's compliance with the protocol requirements, or confound the reliability of the data acquired

4. Be an Evofem, ClinicalRM, or clinical site employee regardless of direct involvement in research activities, or their close relative

5. Pregnant (or actively trying to become pregnant), or breast-feeding

6. Women who have undergone a total hysterectomy (had uterus and cervix removed)

7. Inability to provide informed consent

8. A subject with a history or expectation of noncompliance with medications or intervention protocol

9. Have engaged in sexual intercourse, douching or used of any form of vaginal suppository or intravaginal device for 24 hours prior to enrollment (may be enrolled at a later date if all other criteria are met)

10. Menstruating at enrollment (may be enrolled at a later date if all other criteria are met)

11. Women who are currently being treated, or have been treated, for a period of 14 days prior to enrollment, with specific antibiotics known to be used for the treatment of CT or GC:

    1. Azithromycin
    2. Erythromycin
    3. Tetracycline
    4. Minocycline
    5. Doxycycline
    6. Levofloxacin
    7. Ofloxacin
    8. Ceftriaxone
    9. Cefixime

12. In the opinion of the Investigator, has signs/symptoms that indicate persistence of chlamydia or gonorrhea infection diagnosed at screening, new interval infection and/or a failure to comply with or complete the prescribed treatment regimen following a positive screening NAAT.

13. Women who regularly use douches, vaginal medications, products, or suppositories

14. Women who are currently using contraceptive products that are directly delivered to the vaginal mucosa, such as diaphragms, vaginal rings (e.g. NuvaRing®), spermicides, or any vaginally applied or inserted products containing nonoxynol-9.

15. Children, pregnant women, prisoners, and other vulnerable populations

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
EVO100	EVO100	A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.

Primary Outcome Measures

Name	Time	Method
Urogenital CT Infection	16 weeks	Proportion of subjects who experience urogenital CT infection during the study intervention period (incident infection of CT).

Secondary Outcome Measures

Name	Time	Method
Urogenital GC Infection	16 weeks	Proportion of subjects who experience urogenital GC infection during the study intervention period (incident infection of GC).

Trial Locations

Locations (50)

Coastal Clinical Research, Inc.; 🇺🇸 Mobile, Alabama, United States

Mobile OB-GYN, PC; 🇺🇸 Mobile, Alabama, United States

MedPharmics, LLC; 🇺🇸 Phoenix, Arizona, United States

Precision Trials AZ, LLC; 🇺🇸 Phoenix, Arizona, United States

Eclipse Clinical Research; 🇺🇸 Tucson, Arizona, United States

California Center for Clinical Research; 🇺🇸 Arcadia, California, United States

Hope Clinical Research; 🇺🇸 Canoga Park, California, United States

United Clinical Research; 🇺🇸 Huntington Park, California, United States

Medical Center for Clinical Research - Wake Research; 🇺🇸 San Diego, California, United States

Optimus Medical Group, Inc.; 🇺🇸 San Francisco, California, United States

Scroll for more (40 remaining)